- Abbott India‘s 4Q net income surpassed expectations, standing at 2.87 billion rupees, a steady rise of 24% year on year (y/y).
- Revenue for the company came up to 14.4 billion rupees, marking a 7.5% y/y increase. However, this figure slightly missed the estimated 14.76 billion rupees.
- Also noteworthy is the total cost increase of 4.6% y/y, amounting to 11.3 billion rupees.
- Investors will be happy to see a dividend per share of 410 rupees.
- Analysts’ opinions on Abbott India show that there are 6 buys, 1 hold and 1 sell recommendation.
- It is important to note that these comparisons are based on the company’s original disclosures.
A look at Abbott India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott India Limited, a renowned manufacturer of pharmaceutical and medical products, agrochemicals, and animal health products, showcases a promising long-term outlook based on a comprehensive analysis of its various aspects. With a sturdy resilience score of 5, the company demonstrates a high capability to endure challenging times and bounce back efficiently. Additionally, Abbott India scores impressively in the dividend category with a solid 4, indicating a reliable and consistent dividend payment history, which could attract long-term investors seeking stable returns.
Moreover, the company exhibits strong momentum with a score of 4, highlighting its ability to maintain its forward motion and potentially outperform the market. When it comes to growth prospects, Abbott India secures a score of 3, signifying a moderate but steady upward trajectory in expanding its business operations. While the value score of 2 suggests some room for improvement in terms of the company’s valuation relative to its peers, Abbott India‘s overall outlook remains positive, supported by its robust performance across key factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
